Clinical Study on Calcitriol Combined with Sirolimus in the Treatment of Chronic Primary Immune Thrombocytopenia Patients.
10.19746/j.cnki.issn.1009-2137.2021.06.038
- Author:
Qi LI
1
;
Hong-Yang KANG
1
;
Ling FAN
1
;
Ling ZHANG
1
;
Jie LIU
1
;
Chang-Qing TONG
2
;
Bin ZHANG
3
Author Information
1. Department of Hematology,The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, Hebei Province, China.
2. Department of Hematology,The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, Hebei Province, China.E-mail: totoromika@163.com.
3. Department of Laboratory Medicine, The First Affiliated Hospital of Hebei North University, Zhangjiakou 075000, Hebei Province, China.
- Publication Type:Randomized Controlled Trial
- MeSH:
Calcitriol;
Humans;
Platelet Count;
Purpura, Thrombocytopenic, Idiopathic/drug therapy*;
Quality of Life;
Sirolimus
- From:
Journal of Experimental Hematology
2021;29(6):1911-1916
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the clinical efficacy of calcitriol combined with sirolimus in the treatment of chronic primary immune thrombocytopenia (cITP) patients.
METHODS:A total of 146 adult cITP patients reated in the First Affiliated Hospital of Hebei North University from March 2017 to March 2020 were randomly divided into observation group (73 cases) and control group (73 cases) according to random number table. The control group was treated with oral sirolimus capsule, the observation group was treated with oral calcitriol capsule combined with sirolimus capsule, and the curative effect of the 2 groups was evaluated after continuous treatment for 6 weeks. The changes of World Health Organization (WHO) bleeding grade, laboratory related index, including peripheral blood regulatory T cell (Treg), serum 1,25-dihydroxy-vitamin D
RESULTS:The total effective rate of the observation group was 79.5% (58/73), which was significantly higher than 64.4% (47/73) of the control group (P<0.05). The revised WHO bleeding grades after treatment were significantly better than those before treatment in the 2 groups (P<0.05), but the observation group was improved more significantly than the control group (P<0.05). After treatment, platelet count (PLT), peripheral blood Treg cell ratio, and serum 1,25(OH)
CONCLUSION:The overall efficacy of calcitriol combined with sirolimus in the treatment of cITP in adults is satisfactory, which can effectively alleviate patient's condition, improve the quality of life, further increase the platelet level and decrease the expression of VDR in peripheral blood lymphocyte, the mechanism may be related to increasing the level of serum 1,25(OH)
